Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02738398 · ClinicalTrials.gov registry record · NA
FDG PET/CT in Lung Cancer Staging
A NA study of Non-small Cell Lung Cancer (NSCLC), sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02738398 is a NA study of Non-small Cell Lung Cancer (NSCLC) that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 30 participants, below the 288-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02738398, a NA study of Non-small Cell Lung Cancer (NSCLC), has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Prospective study of the effects of image acquisition and reconstruction parameters on accuracy of FDG PET/CT mediastinal nodal staging in NSCLC
Conditions Studied
Interventions
- RADIATION FDG PET/CT
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-04 |
| Est. Completion | 2026-01-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02738398
The ClinicalTrials.gov registry entry for NCT02738398 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 288-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (90% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 1 intervention - of which FDG PET/CT is the first listed.
NCT02738398 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02738398 about?
NCT02738398 is a clinical study titled "FDG PET/CT in Lung Cancer Staging". Prospective study of the effects of image acquisition and reconstruction parameters on accuracy of FDG PET/CT mediastinal nodal staging in NSCLC
What is the current status of trial NCT02738398?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2016-04. Estimated completion is 2026-01-27.
What conditions does trial NCT02738398 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT02738398?
The interventions under investigation include: FDG PET/CT (RADIATION).
Who is sponsoring clinical trial NCT02738398?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02738398 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy
RECRUITING · NA
-
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
RECRUITING · Phase 3
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.